About Geneoscopy
Geneoscopy is a precision medicine company focused on transforming gastrointestinal health through innovative molecular diagnostic tests. The company has developed a proprietary stool-derived eukaryotic RNA (seRNA) technology platform that enables noninvasive screening, detection, and monitoring of gastrointestinal diseases. Geneoscopy's flagship product, ColoSense, is the first FDA-approved RNA-based stool test for colorectal cancer screening in adults aged 45 and older. The company's mission is to empower patients and healthcare providers with molecular-based tests that help prevent, detect, and monitor disease. By offering a convenient, at-home collection method, Geneoscopy addresses the significant gap in colorectal cancer screening rates, where over 40% of eligible patients fail to get screened due to the inconvenience and invasive nature of colonoscopies. Beyond colorectal cancer, Geneoscopy is advancing applications of its stool RNA technology to monitor disease activity and predict therapeutic response in inflammatory bowel disease. The company partners with biopharma organizations and research institutions to develop companion diagnostics and clinical trial tools. Geneoscopy's platform-agnostic RNA extraction technology can be evaluated using next-generation sequencing, ddPCR, qPCR, molecular barcoding, or microarray technology, providing comprehensive insights into the stool-derived transcriptome for various gastrointestinal disease indications.
Mission & Story
Mission
To empower patients and healthcare providers to transform gastrointestinal health with our innovative tests that help prevent, detect, and monitor disease.
Founding Story
Co-founders Andrew Barnell and Dr. Erica Barnell established Geneoscopy with a commitment to bridging the gap in colorectal cancer screening rates. Dr. Erica Barnell completed her MD/PhD at Washington University School of Medicine in Molecular Genetics and Genomics from the McDonnell Genome Institute, where she spearheaded the clinical and regulatory development of ColoSense. Andrew Barnell brought experience from healthcare investment banking at J.P. Morgan and private equity at Lindsay Goldberg.
Clinical Focus
Medical conditions and clinical areas addressed by Geneoscopy.
Who It Serves
Milestones & Awards
Recent Milestones
FDA approval of ColoSense as the first RNA-based stool test for colorectal cancer screening. Dr. Erica Barnell completed MD/PhD in 2023. Expansion into inflammatory bowel disease monitoring applications.
Awards & Recognition
Dr. Erica Barnell named to Forbes' 30 Under 30 in 2020
Key Partnerships
Social & Media
Latest Updates
Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
Geneoscopy to Participate in Upcoming Investor Conferences
Geneoscopy’s ColoSense® Test Included as a Preferred Option in the American Cancer Society Colorectal Cancer Screening Guidelines Update
CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent
Company Details
- Headquarters
- St. Louis, MO, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.